Home › Funds › Lynx1 Capital Management LP › DNLI
Lynx1 Capital Management LP position in DNLI
DENALI THERAPEUTICS INC · Health Care
Lynx1 Capital Management LP reported holding 11,658 shares of DNLI (DENALI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$300K, representing 0.03% of its reported portfolio and ranking #18 among its reported holdings. Lynx1 Capital Management LP has disclosed DNLI holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's DNLI position evolved
Lynx1 Capital Management LP first disclosed a stake in DNLI in Q3 2025 at 261,687 shares (US$3.8M). The position peaked in Q1 2026 at 1,880,303 shares, worth US$36.1M. Across 4 filings, Lynx1 Capital Management LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 11,658 shares valued at US$300K — a reduction of -1,868,645 shares quarter over quarter.. Notable position changes include a 564% increase in Q4 2025 (shares rose 16% over the following quarter), a 99% trim in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 261.69K | $3.80M | New |
| Q4 2025 | 1.74M | $28.71M | Add |
| Q1 2026 | 1.88M | $36.10M | Add |
| Q2 2026 | 11.66K | $299.84K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNLI and 13F data
DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $180.37M · Q2 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Crestline Management, L.P. 1.91M sh · $49.14M · Q2 2026
- Foresite Capital Management VI LLC 1.40M sh · $35.92M · Q2 2026
- Siren, L.L.C. 1.40M sh · $35.92M · Q2 2026
- ADAR1 Capital Management, LLC 1.03M sh · $26.47M · Q2 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held DNLI?
Lynx1 Capital Management LP has disclosed DNLI holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Lynx1 Capital Management LP's current position in DNLI?
As of Q2 2026, Lynx1 Capital Management LP holds 11.66K shares of DNLI (DENALI THERAPEUTICS INC), valued at $299.84K, representing 0.03% of its reported portfolio and ranking #18.
Has Lynx1 Capital Management LP been buying or selling DNLI?
In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP reduced its position in DNLI. The position peaked in Q1 2026 at 1.88M shares.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.